Yuflyma, Biosimilar to Humira, Approved in EU for Chronic Inflammatory Diseases

Yuflyma, Biosimilar to Humira, Approved in EU for Chronic Inflammatory Diseases

287512

Yuflyma, Biosimilar to Humira, Approved in EU for Chronic Inflammatory Diseases

The European Commission (EC) has granted marketing authorization to Celltrion Healthcare‘s Yuflyma (CT-P17), a biosimilar to Humira (adalimumab). The marketing authorization includes all indications for which AbbVie’s Humira is approved, including adult and pediatric Crohn’s disease and ulcerative colitis, two forms of inflammatory bowel disease (IBD). Biosimilars are biological products with similar properties to an original product — in this case, Humira — but manufactured by a different company. Of note, a biological product is…

You must be logged in to read/download the full post.